Aficamten
A cardiac myosin inhibitor used in the treatment of hypertrophic cardiomyopathy
| Aficamten | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB123456 |
| ChemSpider | |
| KEGG | D12345 |
Aficamten is a cardiac myosin inhibitor that is being developed for the treatment of hypertrophic cardiomyopathy (HCM). It is designed to reduce the hypercontractility of the heart muscle, which is a hallmark of this condition.
Mechanism of Action
Aficamten works by selectively inhibiting cardiac myosin, a motor protein responsible for heart muscle contraction. By reducing the activity of myosin, aficamten decreases the force of contraction of the heart muscle, thereby alleviating the symptoms associated with hypertrophic cardiomyopathy. This mechanism helps in reducing the left ventricular outflow tract obstruction, which is a common problem in HCM patients.
Clinical Development
Aficamten is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hypertrophic cardiomyopathy. Early studies have shown promising results in terms of reducing cardiac muscle contractility and improving symptoms in patients with obstructive HCM.
Pharmacokinetics
The pharmacokinetic profile of aficamten includes oral administration, with studies indicating a favorable absorption and distribution in the body. The drug is metabolized primarily in the liver and excreted through the kidneys. The half-life of aficamten allows for once-daily dosing, which is convenient for patients.
Potential Side Effects
As with any medication, aficamten may have side effects. Commonly reported side effects include dizziness, fatigue, and hypotension. It is important for patients to be monitored regularly to manage any adverse effects that may arise during treatment.
Research and Future Directions
Research is ongoing to further understand the long-term effects of aficamten and its potential use in other cardiac conditions. Studies are also exploring the combination of aficamten with other therapies to enhance its therapeutic effects.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
